Who is sponsoring De-Tox?

De-Tox is sponsored by Universitas Padjadjaran.

What condition does De-Tox study?

De-Tox studies Toxoplasmosis, Cerebral.

What drugs are being tested in De-Tox?

Interventions: Dexamethasone, Placebo.

What is the status of De-Tox?

De-Tox is currently RECRUITING.

Last reviewed 2024-07-02 · How we verify

Adjunctive Dexamethasone for Cerebral Toxoplasmosis: a Double-blinded Randomized Controlled Trial (De-Tox)

NCT04341155 Phase 2 RECRUITING

Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with proper treatment and 80% without it. The fatality mainly due to the brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given, adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains unclear. Moreover, its safety in immunodeficiency cases is still debatable.

Details

Lead sponsor	Universitas Padjadjaran
Phase	Phase 2
Status	RECRUITING
Enrolment	138
Start date	2021-04-16
Completion	2025-07

Conditions

Toxoplasmosis, Cerebral

Interventions

Dexamethasone
Placebo

Primary outcomes

Mortality — 90 days
Determined by the time from randomization to death (in days)

Countries

Indonesia